The move gives the agency time to weigh a settlement that would allow the deal to close with conditions.
Source link
Tags: acquisitions, Acquisitions/Mergers, Acquisitions/Mergers/Shareholdings, Amgen, AMGN, Anti-Competition Issues, Biopharmaceuticals, Biotechnology Services, C&E Executive News Filter, C&E Industry News Filter, Content Types, corporate, Corporate Actions, corporate crime, Corporate Crime/Legal Action, Corporate/Industrial News, Crime, Crime/Legal Action, Eye Conditions, Factiva Filters, general news, government policy, Health, healthcare, Healthcare/Life Sciences, Horizon Therapeutics, HZNP, industrial news, legal action, life sciences, Medical Conditions, mergers, north america, Ownership Changes, Pharmaceuticals, political, Political/General News, regulation, Regulation/Government Policy, shareholdings, SYND, United States, WSJ-PRO-WSJ.com
